Anakinra in the treatment of rheumatic disease (Q43061720)

13 November 2017

title

Anakinra in the treatment of rheumatic disease (English)

1 reference

13 November 2017

1 reference

Roy Fleischmann

1

1 reference

13 November 2017

publication date

1 May 2006

1 reference

Expert Review of Clinical Immunology

13 November 2017

published in

1 reference

13 November 2017

volume

2

1 reference

13 November 2017

issue

3

1 reference

13 November 2017

page(s)

331-340

1 reference

Cytokine pathways and joint inflammation in rheumatoid arthritis

13 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1586/1744666X.2.3.331

Evolving concepts of rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/1744666X.2.3.331

Twin concordance rates for rheumatoid arthritis: results from a nationwide study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/1744666X.2.3.331

Direct and indirect costs of rheumatoid arthritis to an employer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/1744666X.2.3.331

Direct medical costs and their predictors in patients with rheumatoid arthritis: a three-year study of 7,527 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/1744666X.2.3.331

An assessment of the annual and long-term direct costs of rheumatoid arthritis: the impact of poor function and functional decline

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/1744666X.2.3.331

How does functional disability in early rheumatoid arthritis (RA) affect patients and their lives? Results of 5 years of follow-up in 732 patients from the Early RA Study (ERAS)

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/1744666X.2.3.331

Which patients stop working because of rheumatoid arthritis? Results of five years' follow up in 732 patients from the Early RA Study (ERAS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/1744666X.2.3.331

The impact of rheumatoid arthritis on medical expenditures, absenteeism, and short-term disability benefits

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/1744666X.2.3.331

Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/1744666X.2.3.331

Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/1744666X.2.3.331

Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/1744666X.2.3.331

Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/1744666X.2.3.331

Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumati

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/1744666X.2.3.331

Magnetic resonance imaging for accelerated assessment of drug effect and prediction of subsequent radiographic progression in rheumatoid arthritis: a study of patients receiving combined anakinra and methotrexate treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/1744666X.2.3.331

Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/1744666X.2.3.331

Will our current success in treating rheumatoid arthritis hinder new drug development? That is the question!!

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/1744666X.2.3.331

Beneficial response to anakinra and thalidomide in Schnitzler's syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/1744666X.2.3.331

Rapid responses to anakinra in patients with refractory adult-onset Still's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/1744666X.2.3.331

The clinical course of a child with CINCA/NOMID syndrome improved during and after treatment with thalidomide

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/1744666X.2.3.331

Cytokines and cytokine inhibitors or antagonists in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/1744666X.2.3.331

The pivotal role of interleukin-1 in the clinical manifestations of rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/1744666X.2.3.331

Rheumatoid arthritis. Pathophysiology and implications for therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/1744666X.2.3.331

Detection of cytokines at the cartilage/pannus junction in patients with rheumatoid arthritis: implications for the role of cytokines in cartilage destruction and repair

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/1744666X.2.3.331

Pathogenesis of bone and cartilage destruction in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/1744666X.2.3.331

Mapping receptor binding sites in interleukin (IL)-1 receptor antagonist and IL-1 beta by site-directed mutagenesis. Identification of a single site in IL-1ra and two sites in IL-1 beta.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/1744666X.2.3.331

Interleukin-1 receptor antagonist activity of a human interleukin-1 inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/1744666X.2.3.331

Primary structure and functional expression from complementary DNA of a human interleukin-1 receptor antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/1744666X.2.3.331

Pharmacokinetics of anakinra in subjects with different levels of renal function

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/1744666X.2.3.331

Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/1744666X.2.3.331

A multicentre, double blind, randomised, placebo controlled trial of anakinra (Kineret), a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis treated with background methotrexate

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/1744666X.2.3.331

American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/1744666X.2.3.331

A multicenter, double-blind, dose-ranging, randomized, placebo-controlled study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis: radiologic progression and correlation of Genant and Larsen scores

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/1744666X.2.3.331

Refractory adult onset Still's disease successfully treated with anakinra

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/1744666X.2.3.331

Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/1744666X.2.3.331

De novo CIAS1 mutations, cytokine activation, and evidence for genetic heterogeneity in patients with neonatal-onset multisystem inflammatory disease (NOMID): a new member of the expanding family of pyrin-associated autoinflammatory diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/1744666X.2.3.331

PYPAF7, a novel PYRIN-containing Apaf1-like protein that regulates activation of NF-kappa B and caspase-1-dependent cytokine processing

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/1744666X.2.3.331

Interleukin-1 blockade by anakinra improves clinical symptoms in patients with neonatal-onset multisystem inflammatory disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/1744666X.2.3.331

Response to anakinra in a de novo case of neonatal-onset multisystem inflammatory disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/1744666X.2.3.331

Spectrum of clinical features in Muckle-Wells syndrome and response to anakinra

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/1744666X.2.3.331

Preliminary results of safety and efficacy of the interleukin 1 receptor antagonist anakinra in patients with severe lupus arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/1744666X.2.3.331

Efficacy of anakinra in active ankylosing spondylitis: a clinical and magnetic resonance imaging study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/1744666X.2.3.331

Open label trial of anakinra in active ankylosing spondylitis over 24 weeks

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/1744666X.2.3.331

The safety of anakinra in high-risk patients with active rheumatoid arthritis: six-month observations of patients with comorbid conditions

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/1744666X.2.3.331

Lack of response to anakinra in rheumatoid arthritis following failure of tumor necrosis factor alpha blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/1744666X.2.3.331

The use of anakinra in juvenile arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/1744666X.2.3.331

Measurement of patient outcome in arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/1744666X.2.3.331

Epidemiology and burden of illness of rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/1744666X.2.3.331

Detection of tumor necrosis factor alpha but not tumor necrosis factor beta in rheumatoid arthritis synovial fluid and serum

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/1744666X.2.3.331

Cytokines in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/1744666X.2.3.331

Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/1744666X.2.3.331

Socio-economic consequences of rheumatoid arthritis in the first years of the disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/1744666X.2.3.331

Therapeutic strategies for rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/1744666X.2.3.331

The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/1744666X.2.3.331

A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/1744666X.2.3.331

Validation of rheumatoid arthritis improvement criteria that include simplified joint counts

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/1744666X.2.3.331

Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/1744666X.2.3.331

Anakinra in mutation-negative NOMID/CINCA syndrome: comment on the articles by Hawkins et al and Hoffman and Patel

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/1744666X.2.3.331

Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/1744666X.2.3.331

Anakinra, a recombinant human interleukin-1 receptor antagonist (r-metHuIL-1ra), in patients with rheumatoid arthritis: A large, international, multicenter, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/1744666X.2.3.331

Long-term safety and maintenance of clinical improvement following treatment with anakinra (recombinant human interleukin-1 receptor antagonist) in patients with rheumatoid arthritis: extension phase of a randomized, double-blind, placebo-controlled

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/1744666X.2.3.331

Dramatic improvement with anakinra in a case of chronic infantile neurological cutaneous and articular (CINCA) syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/1744666X.2.3.331

IL-1RA in refractory systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/1744666X.2.3.331

Ankylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/1744666X.2.3.331

Results of anakinra treatment in rheumatoid arthritis patients previously treated with tumor necrosis factor alpha blockade: comment on the article by Buch et al

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/1744666X.2.3.331

21 January 2018

Identifiers

DOI

10.1586/1744666X.2.3.331

1 reference

release_s574bj6i2veineo7xfaozzjdeu

13 November 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/s574bj6i2veineo7xfaozzjdeu

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference